|
|
Vol. 24.01 – 16 January, 2023
|
|
|
|
|
|
|
|
Scientists conducted a multicenter, dose-escalation, phase I trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma, ovarian cancer, and head and neck cancer. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers demonstrated successful implantation of human pluripotent stem cell-derived islets in a new transplantation site in the abdomen, the subanterior rectus sheath, in eight nonhuman primates.
[Nature Metabolism]
|
|
|
|
|
|
Scientists investigated whether CAR T cells could be used as an adjuvant therapy to clear residual cancer cells. They tested the feasibility of this approach in two partial resection xenograft models using mesothelin-specific CAR T cells.
[Science Advances]
|
|
|
|
|
|
The authors investigated how vancomycin-induced gut microbiota dysbiosis affects CAR T immunotherapy using multiple preclinical models as well as clinical correlates.
[Molecular Therapy]
|
|
|
|
|
|
Investigators evaluated mesenchymal-epithelial transition factor (c-Met) expression and its prognostic role in lung adenocarcinoma, and then employed the previous sequence of c-Met-Fab to design a novel c-Met-CAR and construct c-Met-CAR-natural killer cells.
[Pharmacological Research]
|
|
|
|
|
|
The authors demonstrated that multipotent progenitors promoted T cell production of hematopoietic stem cells when both cell types were cotransplanted in mice.
[Experimental & Molecular Medicine]
|
|
|
|
|
|
Investigators revealed that injury caused by glossopharyngeal nerve transection triggered the remaining differentiated K8-positive taste receptor cells to dedifferentiate and acquire transient progenitor cell-like states during regeneration. [Experimental & Molecular Medicine]
|
|
|
|
|
|
Scientists used CRISPR-Cas9 gene editing methods to integrate an anti-GD2 CAR into the AAVS1 locus of human pluripotent stem cells.
[Stem Cell Reports]
|
|
|
|
|
|
Researchers characterized the NCG mouse model for toxicity, engraftment, and tumorigenicity assessments of cell therapies, using CD34+ human hematopoietic stem cell adult mobilized cells with two myeloablation regimens. [International Journal of Toxicology]
|
|
|
|
|
|
|
|
The authors present a comprehensive summary of the currently available chemically engineered tools, introduce their application in advanced diagnosis and precision therapy, and discuss the current challenges and future opportunities. [Chemical Society Reviews]
|
|
|
|
|
|
|
|
Physician-scientists at Stanford Medicine have received about $18 million from the California Institute for Regenerative Medicine for two projects to advance cutting-edge treatments for children: a clinical trial to improve kidney transplants, and a study of a gene-editing treatment for a rare disease. [Stanford Medicine]
|
|
|
|
|
|
|
|
February 9 – 12, 2023 Cancun, Mexico
|
|
|
|
|
|
|
|
|
|
|
University of California Los Angeles – Los Angeles, California, United States
|
|
|
|
|
|
|
Aspect Biosystems – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
The University of Texas MD Anderson Cancer Center – Houston, Texas, United States
|
|
|
|
|
|
|
Dankook University – Seoul, South Korea
|
|
|
|
|
|
|
Columbia University – New York, New York, United States
|
|
|
|
|
|